期刊文献+

前列腺癌的分子病理学研究进展 被引量:8

下载PDF
导出
摘要 随着对前列腺癌分子病理学研究的深入,多种与前列腺癌有关的基因及其作用机制受到关注,其中启动子的甲基化在前列腺癌早期诊断中的应用,一些体细胞基因异常在前列腺癌发生发展中的作用及其应用于前列腺癌诊断及治疗的前景成为研究热点。53BP1介导的DNA损伤应答通路目前也被证明参与了前列腺癌的发生。这些发现将为前列腺癌发病机制的阐明、前列腺癌的诊断及治疗、预后及疗效评价提供全新的视角。本文将对该领域的一些研究进展做一综述。
出处 《临床与实验病理学杂志》 CAS CSCD 北大核心 2011年第6期632-635,共4页 Chinese Journal of Clinical and Experimental Pathology
基金 上海市浦江人才计划(08PJ1407400) 迈新.病理基金
  • 相关文献

参考文献36

  • 1Ahmed H.Promoter methylation in prostate cancer and its application for the early detection of prostate cancer using serum and urine samples[J].Biomark Cancer,2010(2):17-33.
  • 2Bryzgunova O E,Morozkin E S,Yarmoschuk S V,et al.Methylation-specific sequencing of GSTP1 gene promoter in circulating/extracellular DNA from blood and urine of healthy donors and prostate cancer patients[J].Ann N Y Acad Sci,2008,1137:222-5.
  • 3Lee W H,Morton R A,Epstein J I,et al.Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis[J].Proc Natl Acad Sci USA,1994,91(24):11733-7.
  • 4Nakayama M,Gonzalgo M L,Yegnasubramanian S,et al.GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer[J].J Cell Biol,2004,91(3):540-52.
  • 5Meiers I,Shanks J H,Bostwick D G.Glutathione S-transferase pi (GSTP1) hypermethylation in prostate cancer[J].Pathology,2007,39(3):299-304.
  • 6Richiardi L,Fiano V,Vizzini L,et al.Promoter methylation in APC,RUNX3,and GSTP1 and mortality in prostate cancer patients[J].J Clin Oncol,2009,27(19):3161-8.
  • 7任加强,陈忠清,郑莉,陈琦,李华,朱虹光.前列腺特异性膜抗原和前列腺特异性抗原表达强度与前列腺癌Gleason评分之间的相关性研究[J].中华肿瘤杂志,2004,26(12):735-738. 被引量:5
  • 8Perner S,Hofer M D,Kim R,et al.Prostate-specific membrane antigen expression as a predictor of prostate cancer progression[J].Hum Pathol,2007,38(5):696-701.
  • 9Schmittgen T D,Teske S,Vessella R L,et al.Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients[J].Int J Cancer,2003,107(2):323-9.
  • 10Zhang L,Wang C Y,Yang R,et al.Real-time quantitative RT-PCR assay of prostate-specific antigen and prostate-specific membrane antigen in peripheral blood for detection of prostate cancer micrometastasis[J].Urol Oncol,2008,26(6):634-40.

二级参考文献32

  • 1李科,杨红,董丹丹.抗体鸡尾酒p504s/p63标记在前列腺癌诊断中的应用[J].临床与实验病理学杂志,2006,22(3):372-372. 被引量:2
  • 2[1]Maehama T,Dixon JE.The tumor suppressor,PTEN/MMAC1,dephosphorylates the lipid second messenger phosphatidylinositol 3,4,5-triphosphate.J Biol Chem,1998,273:13375.
  • 3[2]Ramaswamy S,Nakarrutra N,Vazquez F,et al.Regulation of G1progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway.Proc Natl Acad Sci USA,1999,96:2110.
  • 4[3]Cains P,Okami K,Halachmi N,et al.Frequent inactivation of PTEN/MMAC1 in primary prostate cancer.Cancer Res,1997,57:4997.
  • 5[4]Vlietstra RJ,van-Alewijk DC,Hermans KG,et al.Frequent inactivation of PTEN in prostate cancer cell lines and xenografts.Cancer Res,1998,58:2720.
  • 6[5]Wang YE,Wu X,Suzuki H,et al.Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression.Proc Natl Acad Sci USA,1998,95:5246.
  • 7[6]DongJT,Li CL,Sipe TW,etal.Mutation of PTEN/MMAC1 in primary prostate cancer from Chinese patient.Clin Cancer Res,2001,7:304.
  • 8[7]Rasheed BK,Stenzel TT,Melendon RE,et al.PTEN gene mutation are seen in high-grade but not in low-grade gliomas.Cancer Res,1997,57:4187.
  • 9[8]Suzuki H,Freije D,Nusskem DR,et al.Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues.Cancer Res,1998,58:204.
  • 10[9]Cairns P,Evron E,Okami K,et al.Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancer.Oncogene,1998,16:3215.

共引文献15

同被引文献79

  • 1《前列腺癌诊断治疗指南》解读[J].泌尿外科杂志(电子版),2009(2):53-54. 被引量:5
  • 2赵峰,邢虎,薛玉,刘敏,王伟华,张歆,陈宝定,吴新财.经直肠腔内彩色多普勒超声检查对前列腺疾病诊断的临床价值[J].江苏大学学报(医学版),2006,16(4):313-316. 被引量:4
  • 3杨明莹,王云娥.60例前列腺癌患者围手术期健康知识需求与分析[J].国际护理学杂志,2006,25(11):924-926. 被引量:1
  • 4Rubin M A,Putzi M,Mucci N,et al.Rapid (“warm”) autopsy study for procurement of metastatic prostate cancer[J].Clin Cancer Res,2000,6(3):1038-45.
  • 5Djavan B,Milani S,Remzi M.Prostate biopsy:who,how and when.An update[J].Can J Urol,2005,12(Suppl 1):44-8.
  • 6Rodón N,Trías I,Verdú M,et al.Diagnostic and predictive value of urine PCA3 gene expression for the clinical management of patients with altered prostatic specific antigen[J].Actas Urol Esp,2014,38(3):150-5.
  • 7Busetto G M,De Berardinis E,Sciarra A,et al.Prostate cancer gene 3 and multiparametric magnetic resonance can reduce unnecessary biopsies:decision curve analysis to evaluate predictive models[J].Urology,2013,82(6):1355-60.
  • 8Bussemakers M J,van Bokhoven A,Verhaegh G W,et al.DD3:a new prostatespecific gene,highly overexpressed in prostate cancer[J].Cancer Res,1999,59(23):5975-9.
  • 9de Kok J B,Verhaegh G W,Roelofs R W,et al.DD3 (PCA3),a very sensitive and specific marker to detect prostate tumors[J].Cancer Res,2002,62(9):2695-8.
  • 10Schalken J A,Hessels D,Verhaegh G.New targets for therapy in prostate cancer:differential display code 3 (DD3(PCA3)),a highly prostate cancerspecific gene[J].Urology,2003,62(5 Suppl 1):34-43.

引证文献8

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部